BOTHELL, Wash., Dec. 29 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary cGMP hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that it has joined the Biomedical Excellence for Safer Transfusion (BEST) Collaborative, an international consortium of leading scientific, clinical, and commercial partners whose mission is to explore collaborative ways to improve transfusion-related services through standardization of analytic techniques, development of new procedures and execution of clinical trials in hemotherapy.
Zbigniew "Ziggy" M. Szczepiorkowski, MD, PhD, co-chair of the BEST cellular therapy team and Associate Professor of Pathology and of Medicine at Dartmouth Medical School, commented on the addition of BioLife Solutions as a new corporate member of BEST by stating, "We're very pleased to welcome BioLife to the BEST Collaborative. BioLife joins other corporate members in the quest to advance the field of transfusion medicine and to work with world leading experts. Results from recent initial safety studies conducted by BioLife and submission of FDA Master Files understandably elevates the profile of the company in the field of transfusion medicine in the US and internationally. We look forward to mutually beneficial scientific collaboration with BioLife and other BEST corporate members to identify ways to extend the shelf-life and improve the transportation logistics as well as post-preservation viability and functional yield of transfusion-related source material and derived cell-based clinical products."
Mike Rice, BioLife's chairman and CEO, noted "Since its formation, the scientific members of BEST have collectively published over 50 peer reviewed scientific articles related to efforts to continually improve quality, safety and efficiency in transfusion medicine. We view our relationship with BEST as highly strategic and a means to continue to demonstrate the scientific differentiation of our products and how they enable measurable improvement in several aspects of transfusion-related biopreservation processes."
About BioLife Solutions, Inc:
BioLife Solutions develops and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's cGMP products are serum-free and protein-free, fully defined, and formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides research and clinical organizations significant improvement in post-preservation cell and tissue viability and function. For more information please visit http://www.biolifesolutions.com.
About BEST Collaborative:
The BEST Collaborative is an international research organization that works collaboratively to explore ways to improve transfusion-related services through standardization of analytic techniques, development of new procedures and execution of clinical trials in hemotherapy. The scientific members of BEST represent a broad diversity of interests and high levels of accomplishment. The manufacturer members of BEST span the gamut of companies engaged with blood collecting, processing, and transfusing organizations worldwide to provide a safe and adequate blood supply. For more information please visit http://www.bestcollaborative.org/.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Media Relations: Investor Relations: Len Hall Matt Clawson Allen & Caron Inc Allen & Caron Inc (949) 474-4300 (949) 474-4300 email@example.com firstname.lastname@example.org
|SOURCE BioLife Solutions, Inc.|
Copyright©2008 PR Newswire.
All rights reserved